A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Recruiting · Phase 2 · NCT06952699
Conditions: Narcolepsy Type 2
At a glance
- Research payments reported, 2025
- $780,014
- U.S. investigators named
- 11
- Sites paid
- 15
- Planned or actual enrollment
- 88
About the trial
- Sponsor
- Takeda
- Tested
- TAK-360 (drug), Placebo (other)
- Dates
- Started 2025-05-06; completion 2026-11-30
- Results posted
- Not yet
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that a…
From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $780,014 in research payments for this study in 2025 (67 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Emmanuel J. Mignot, M.D Sleep Medicine · Stanford, CA
- Andrew O. Schreiber, MD Neurosurgery · Santa Ana, CA
- Jonathan A. Olin, M.D. Sleep Medicine · Ft Carson, CO
- Akinyemi O. Ajayi, MD Pediatric Pulmonology · Winter Park, FL
- Dragos G. Zanchi, M.D Pulmonology · Brandon, FL
- Joseph M. Ojile, M.D. Pulmonology · Saint Louis, MO
- Daniel T. Garber, M.D. Sleep Medicine · Concord, NC
- Thomas P. Stern, M.D. Pulmonology · Huntersville, NC
- Bruce C. Corser, MD Pulmonology · Cincinnati, OH
- Nagwa N. Lamaie, M.D. Family Medicine · San Antonio, TX
- Michael J. Strunc, MD Child Neurology · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Intrepid Research LLC $425,789
- Research Carolina Elite LLC $65,162
- Central Florida Pediatric Sleep Disorders Institute $54,423
- Stanford Health Care, CA $47,791
- Advanced Respiratory and Sleep Medicine $39,477
- Sds Clinical Trials Inc $33,915
- Delta Waves Inc $14,482
- Meris Clinical Research LLC $14,013
- Sleep Therapy and Research Center LLC $13,820
- Childrens Specialty Group PLLC $13,163
- Advanced Respiratory and Sleep $12,496
- Sds Clinical Trials $11,996
- $11,000
- Clayton Sleep Institute LLC $9,425
- Bogan Sleep Consultants LLC $9,425
- Sleep Therapy and Research Cen $3,637
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.